ENLV
Income statement / Annual
Last year (2023), Enlivex Therapeutics Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Enlivex Therapeutics Ltd.'s net income was -$29.07 M.
See Enlivex Therapeutics Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$2.28 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$835,000.00 |
$777,000.00 |
$546,000.00 |
$286,000.00 |
$297,000.00 |
$121,000.00 |
$12,000.00 |
$25,000.00 |
$17,000.00 |
$0.00 |
| Gross Profit |
-$835,000.00 |
-$777,000.00 |
-$546,000.00 |
$1.99 M |
-$297,000.00 |
-$121,000.00 |
-$12,000.00 |
-$25,000.00 |
-$17,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0.87 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$19.24 M
|
$18.69 M
|
$12.88 M
|
$6.09 M
|
$5.72 M
|
$4.26 M
|
$2.52 M
|
$8.88 M
|
$7.69 M
|
$4.44 M
|
| General & Administrative
Expenses |
$6.14 M
|
$6.70 M
|
$6.24 M
|
$3.60 M
|
$2.75 M
|
$937,000.00
|
$2.96 M
|
$6.99 M
|
$6.95 M
|
$2.64 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$479,000.00
|
$0.00
|
$829,000.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.14 M
|
$6.70 M
|
$6.24 M
|
$3.60 M
|
$2.75 M
|
$937,000.00
|
$3.44 M
|
$6.99 M
|
$7.78 M
|
$2.64 M
|
| Other Expenses |
$4.02 M |
$402,000.00 |
$167,000.00 |
$97,000.00 |
$145,000.00 |
$0.00 |
$0.00 |
$0.00 |
-$829,000.00 |
$0.00 |
| Operating Expenses |
$29.40 M |
$25.80 M |
$19.29 M |
$9.79 M |
$8.62 M |
$5.30 M |
$5.96 M |
$15.87 M |
$15.48 M |
$7.08 M |
| Cost And Expenses |
$29.40 M |
$25.80 M |
$19.29 M |
$9.79 M |
$8.62 M |
$5.30 M |
$5.96 M |
$15.87 M |
$15.48 M |
$7.08 M |
| Interest Income |
$1.57 M |
$835,000.00 |
$120,000.00 |
$225,000.00 |
$238,000.00 |
$138,000.00 |
$39,000.00 |
$90,000.00 |
$186,000.00 |
$85,000.00 |
| Interest Expense |
$14,000.00 |
$5.26 M |
$328,000.00 |
$6,000.00 |
$7,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$835,000.00
|
$777,000.00
|
$546,000.00
|
$286,000.00
|
$297,000.00
|
$121,000.00
|
$12,000.00
|
$25,000.00
|
$17,000.00
|
$5,000.00
|
| EBITDA |
-$28.22 M
|
-$25.02 M
|
-$18.74 M
|
-$9.50 M
|
-$9.08 M
|
-$5.18 M
|
-$5.91 M
|
-$15.78 M
|
-$15.31 M
|
-$7.08 M
|
| EBITDA Ratio |
0 |
0 |
0 |
-3.18 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
-4.3
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$327,000.00
|
-$5.26 M
|
$4.82 M
|
-$2.04 M
|
-$765,000.00
|
$1.06 M
|
-$67,000.00
|
-$1.86 M
|
$135,000.00
|
$58,000.00
|
| Income Before Tax |
-$29.07 M |
-$31.06 M |
-$14.47 M |
-$11.82 M |
-$9.38 M |
-$4.24 M |
-$5.92 M |
-$15.81 M |
-$15.34 M |
-$7.02 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
-5.19
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$11.35 M |
-$4.82 M |
$2.04 M |
$765,000.00 |
$1.06 M |
$28,000.00 |
$216,000.00 |
$24,000.00 |
$0.00 |
| Net Income |
-$29.07 M |
-$42.41 M |
-$9.65 M |
-$13.86 M |
-$10.15 M |
-$4.24 M |
-$5.95 M |
-$16.02 M |
-$15.37 M |
-$7.02 M |
| Net Income Ratio |
0 |
0 |
0 |
-6.09 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-1.56 |
-2.31 |
-0.54 |
-1.05 |
-1.17 |
-1.21 |
-14.35 |
-40.29 |
-43.19 |
-22.91 |
| EPS Diluted |
-1.56 |
-2.31 |
-0.54 |
-1.05 |
-1.17 |
-1.21 |
-13.88 |
-40.29 |
-43.19 |
-22.91 |
| Weighted Average Shares
Out |
$18.57 M
|
$18.39 M
|
$17.86 M
|
$13.17 M
|
$8.65 M
|
$3.51 M
|
$414,204.00
|
$397,655.00
|
$355,762.00
|
$306,490.00
|
| Weighted Average Shares
Out Diluted |
$18.57 M
|
$18.39 M
|
$17.86 M
|
$13.17 M
|
$8.65 M
|
$3.51 M
|
$428,241.00
|
$397,655.00
|
$355,762.00
|
$306,490.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
